BPC-157 vs GHK-Cu for tissue repair: different pathways, overlapping results

Pull up the longevity-and-injury thread on any peptide forum and you’ll find BPC-157 and GHK-Cu within three replies of each other. Different shelves of the same shop. Both filed under tissue repair. Both pitched as the molecules to keep on hand whenever the body needs to put itself back together.

The pitch papers over the part that matters. BPC-157 and GHK-Cu have almost nothing in common except the marketing category. Different parent molecules, different anatomies, different evidence stacks — and one of them is on the July 2026 FDA review while the other isn’t anywhere near it. Whichever one tissue repair means in a given week is doing two unrelated jobs in two unrelated places.

So before you stack them, alternate them, or pick one as the real recovery peptide, the honest move is the same as ever. Lay the two side-by-side and look at what each one is actually carrying.

Two peptides from two unrelated corners of biology

These compounds don’t come from neighbouring chapters of the textbook. They don’t come from the same textbook.

BPC-157 is a fifteen-amino-acid fragment of a larger protein called body protection compound — a peptide isolated from human gastric juice in the early 1990s by a Croatian research group led by Predrag Sikirić. The 2025 Pharmaceuticals literature and patent review by Józwiak et al. catalogues the proposed activities: angiogenesis, growth-factor signalling, mucosal protection. The reputation rests on three decades of rat studies where tendon, ligament, gut, and muscle repair runs faster than it does in saline controls.

GHK-Cu is a different animal. The tripeptide GHK — glycine, histidine, lysine, just three residues — is a fragment that occurs naturally in human plasma. On its own it does very little. Bind a copper(II) ion to it and you have the molecule with the reputation: GHK-Cu, the copper-bound complex. The 1979 Journal of Chromatography paper by Pickart, Thaler and Millard is the analytical anchor — the paper that worked out copper and iron co-isolate with the tripeptide during purification, which is why earlier preparations kept losing bioactive material. The story of GHK-Cu as a tissue-repair agent is what Pickart built on top of that observation for the next four decades.

Already, before any clinical data, the two compounds are doing different things in different places. BPC-157 is a gastric-derived peptide proposed to drive blood-vessel growth at injury sites in tendon, ligament, gut, and muscle. GHK-Cu is a copper-handling tripeptide whose mechanism work is overwhelmingly on skin and wound — fibroblasts, the extracellular matrix, the collagen-and-decorin programme. Two different anatomies. Two different molecular routes. One marketing category.

The spec sheet

Pull the basic structural and regulatory facts into one frame, because the marketing flattens these out into two recovery peptides when they are not.

Two things to take from the spec sheet. The mechanism column is not parallel — one row is about new blood vessels into tendon and gut, the other is about copper, ECM remodelling, and skin. And the FDA column is not parallel either — the two compounds are in different waves of the same review process, roughly seven months and one route-of-administration distinction apart. Both rows quietly contradict the tissue-repair stack pitch.

The GHK vs GHK-Cu detail that breaks the comparison if you skip it

There is one thing to clear up before going further, because it changes what the published research actually covers.

The compound the published research base is built on is the copper-bound complex — GHK-Cu, written sometimes as GHK-Cu(II), with the tripeptide chelating a copper ion. The bare tripeptide GHK without copper is a different molecule that behaves differently. Most published activity requires the copper chelation. Cosmetic formulations sometimes use GHK without copper and rely on coordination with endogenous skin copper to become active — which is not the same assumption as injecting the pre-formed copper-bound complex.

This is the part marketing copy elides. GHK, GHK-Cu, copper peptide, and Cu-tripeptide get used interchangeably across product labels, forum posts, and even some review articles. The published activity sits on the copper-bound form. When the rest of this comparison says GHK-Cu, that’s the molecule meant. Anything that takes those findings and applies them to the bare tripeptide is making an inference the chemistry does not support.

The naming detail matters because every claim further down the page rests on the copper-bound complex, not on the three free amino acids floating around your plasma.

What the animal and in vitro evidence shows — BPC-157

The case for BPC-157 in tissue repair is the volume and the consistency of the rat work, and the anatomy it covers.

A 2025 systematic review in orthopaedic sports medicine by Vasireddi, Hahamyan & Salata in HSS J describes BPC-157 as an emerging candidate across tendon, ligament, and bone injury, drawing on preclinical and early clinical findings. A 2026 review by Matek, Matek & Japjec in Pharmaceuticals goes narrower still, looking at BPC-157 alongside growth factors at the junctions where tendon and muscle attach to bone — the spots that take longest to come back. The animal record extends beyond the musculoskeletal column, too: gut, mucosa, dermal wound, even cardiac models, all in rodents.

Treat the picture honestly. The animal volume is real. The proposed mechanism is plausible — angiogenesis at the injury site, blood vessels into damaged tissue, faster repair signal. Almost all of it traces back to one research group across three decades, which means it has not had the outside-lab scrutiny you would want before betting your own shoulder on it.

What the animal and in vitro evidence shows — GHK-Cu

The case for GHK-Cu in tissue repair is older and built on a different anatomy.

The mechanism work is layered. The Pickart, Vasquez-Soltero and Margolina 2015 review in BioMed Research International and the follow-up Pickart and Margolina 2018 paper in the International Journal of Molecular Sciences together lay out a long list of actions across in vitro and animal models. GHK-Cu stimulates the synthesis of collagen, elastin, decorin, and the glycosaminoglycans that give skin its bounce. It modulates the metalloproteinases that break those structures down. It supports dermal fibroblasts, promotes new blood-vessel growth, attracts immune cells to wound sites, and accelerates healing in skin, hair follicles, gastrointestinal tract, bone, and stomach lining in rodents, dogs, and pigs. The native plasma GHK concentration drops with age — the cosmetic and longevity literature leans on that decline to frame the case.

That is a credible mechanism story. The catch is the anatomy. Almost the entire published evidence base — in vitro, animal, and topical human — sits on skin and wound repair, not on the musculoskeletal anatomy BPC-157’s marketing covers. The compound is being sold as a tissue-repair peptide on the back of forty years of dermal-fibroblast and wound-healing work.

The other catch is the source concentration. Almost all of the foundational papers come from Pickart’s lab or co-authored with Margolina, often through his own company, Skin Biology Research & Development. Three decades of mechanism work checked mostly by the people most invested in it has not had the outside scrutiny you would normally want before forming a strong belief about what the molecule does — the same single-lab pattern that haunts the BPC-157 record, applied to a different molecule.

The human file, side-by-side

This is the part the tissue repair stack pitch almost never lays out cleanly, because the published human records are not even pointed in the same direction.

Read those two columns honestly. They are not measuring the same thing.

For BPC-157, the published human file is three papers in a low-impact journal — a two-person intravenous safety pilot by Lee and Burgess in 2025 in Alternative Therapies in Health and Medicine, a sixteen-patient open-label retrospective on intra-articular knee injection by Lee and Padgett in 2021 , and an unrelated bladder-wall pilot in twelve women with interstitial cystitis. As of 2026 the first controlled trial in an actual injury indication, NCT07437547, is recruiting. The hamstring trial is the first time the right question is being asked of the right population, and it has not read out yet.

For GHK-Cu, the published human file is in a different anatomy entirely. Miller and colleagues in 2006 in Archives of Facial Plastic Surgery ran a randomised controlled trial of GHK-Cu skincare in thirteen patients after CO₂ laser facial resurfacing. Blinded evaluators and computer analysis found no significant difference vs placebo on erythema, wrinkles, or overall skin quality. Only patient-reported satisfaction reached significance. That is the entire published randomised human evidence base for GHK-Cu in any form, and it is on a topical skincare regimen, not an injection, and the objective endpoints did not show a benefit. Twenty years on, Mortazavi and colleagues’ 2025 Bioimpacts review frames the modern academic position plainly: the published information on skin permeability, effectiveness, and physicochemical behaviour is insufficient to confirm site-of-action efficacy.

The honest split: BPC-157 has a thin published human file in musculoskeletal and gut indications and a controlled injury trial that just started. GHK-Cu has one small randomised trial in topical skincare with null objective endpoints and no human-controlled evidence in the injectable form people now buy.

The stack them pitch

The forum framing pairs BPC-157 with GHK-Cu the way it pairs BPC-157 with everything else — one handles the inside, the other handles the outside, they cover all the bases, synergy across pathways. The mechanism story is internally consistent for a copywriter and a tradeoff nobody has tested for a clinician.

There is no published controlled trial of the combination. No animal study of the two compounds dosed together in an injury model. No pharmacokinetic study of whether they interact, compete for absorption, or change each other’s clearance. The case for the stack is two single-compound stories stitched together, in two different anatomies, with the implicit assumption that the seams hold.

The seams might hold. That is not the same as them being tested.

The 2026 Sports Medicine review by Mendias and Awan puts the broader posture plainly — both BPC-157 and GHK-Cu sit in their twelve-peptide list of approved and unapproved compounds where rigorous human safety data is scarce and the underlying market operates largely outside regulatory oversight.

Where regulators stand — and where the two peptides split

This is where the comparison stops looking parallel.

The April 2026 Federal Register notice 2026-07361 names seven peptides across the two-day FDA Pharmacy Compounding Advisory Committee meeting on July 23–24, 2026. BPC-157 is on the July 23 session for evaluation under ulcerative colitis. GHK-Cu is not on the docket on either day. That is the asymmetry the tissue-repair stack pitch cannot reconcile.

For BPC-157, the proposed PCAC indication is ulcerative colitis — a gastrointestinal condition, drawing on the compound’s original gastric-mucosa research. Not tendon repair. Not what most buyers actually want it for. PCAC is an advisory committee; it makes a recommendation, and the FDA decides via rulemaking after. A Section 503A listing — the lane PCAC is being asked to open — would let a licensed US compounding pharmacy make a drug for a named patient with a prescription, for the approved indication. A torn shoulder would still be off-label use of a compounded drug, but the regulatory floor underneath the prescription would be materially different from the over-the-counter research-chemical buy that exists today.

For GHK-Cu, the PCAC review is in the second wave, not the first — and the route split is doing more work than it looks. The same April 2026 FDA action that scheduled the July meeting also scheduled a second PCAC meeting before the end of February 2027, and GHK-Cu is on it — alongside Melanotan II, LL-37, Dihexa acetate, and PEG-MGF. The FDA split GHK-Cu by route of administration, and the two halves moved in opposite directions on the 503A bulk substances lists. Injectable GHK-Cu — the form the off-label market actually sells — came off Category 2, the FDA’s do not compound list of substances with significant safety concerns. Non-injectable GHK-Cu went the other way: it was pulled out of Category 1, the under evaluation list that had temporarily let pharmacies compound it under enforcement discretion, so topical GHK-Cu actually lost a safe harbor it used to have. Both forms are slated for the February 2027 PCAC consultation. The injectable form — the form the people on research-chemical sites are now drawing into a syringe — is the reason Category 2 had to move, and that move is precisely why GHK-Cu is on the docket. GHK-Cu has spent most of its regulatory life labelled and sold under the cosmetic-ingredient framework, treated like every other peptide in the ageing-skin aisle. That worked when nobody was injecting it. Now that they are, the agency is scheduled to assess that exact use seven months after the July 2026 meeting, and the result will land in a different form on the same Section 503A list the BPC-157 vote is being held about.

So both compounds are inside the same regulatory process, in different waves, with different indications, and — for GHK-Cu — a route-of-administration split that maps directly onto the cosmetic-vs-injectable distinction at the heart of the off-label market. Both are being sold for tissue repair. The fact that they are seven months and one administration route apart on the same review pipeline is doing more editorial work than the marketing copy lets on.

For competitive athletes, the WADA picture is also asymmetric. BPC-157 is prohibited at all times as a non-approved substance with no recognised therapeutic use. GHK-Cu is not listed by name on the 2026 Prohibited List and is generally treated as permitted, though athletes should verify the current code on the day of testing. Domestic legality and competition eligibility are separate questions, and they stay separate after the July review.

What would actually change the answer

If you wanted the comparison to land on something firmer than two compounds with thin evidence in two different anatomies, here is the short list of evidence neither one has yet.

For BPC-157, the missing piece is the read-out from NCT07437547 — the first controlled human trial in an injury indication. That trial alone won’t settle whether the rat data translates, but it will be the first data point pointed in the right direction.

For GHK-Cu, the missing piece is bigger. A second randomised controlled human trial of GHK-Cu in any tissue-repair indication — not Miller 2006 redone with more subjects, but a fresh trial in baseline ageing skin, or a wound-healing trial in a non-cosmetic population — run by a group independent of Pickart and Margolina. Twenty years on, that trial has not been done. A pharmacokinetic study of subcutaneous GHK-Cu in humans, characterising absorption and tissue concentrations, also does not exist in the published record. And the topical permeability question Mortazavi 2025 wrote out has no published clean answer either: at the concentrations used in commercial products, does GHK-Cu reach the dermal layers where the mechanism work says it should act.

For the stack question, the missing piece is a controlled head-to-head: BPC-157 alone, GHK-Cu alone, both together, placebo, in an injury or wound population with a measured repair endpoint. Until that trial exists, they cover different pathways is a mechanism prediction, not a clinical result.

For both peptides, the missing piece is scrutiny that doesn’t trace back to the discovering lab. Independent reproduction is how a result graduates from interesting to dependable.

So which one, if you’re injured right now

A different question lives inside the headline, and it has a different answer depending on which version of tissue repair you’re after.

If the injury is musculoskeletal — a torn tendon, a strained hamstring, a cranky shoulder — the published anatomical match is on the BPC-157 side. Three decades of rat tendon and ligament work, two review papers in orthopaedic and sports-medicine journals from 2025–2026, and a Phase 2 hamstring trial finally recruiting. The human evidence is still thin, the rodent-to-human gap is still wide, and the regulatory pathway is still pending the July vote — but the anatomy of the published work matches the indication being bought.

If the question is skin and superficial wound, the published anatomical match is on the GHK-Cu side. Forty years of dermal-fibroblast mechanism work, ECM remodelling, collagen and decorin upregulation, animal wound-closure findings — and one randomised human trial showing no significant difference in objective skin endpoints between GHK-Cu skincare and placebo after CO₂ laser resurfacing. The cosmetic literature is real. It does not transfer cleanly to injectable GHK-Cu for systemic tissue repair, which is what is now being sold, because the published human evidence for the injectable form in any indication is essentially zero.

If you isolate the comparison to which one has a regulatory process running this July, the answer is BPC-157. GHK-Cu does not. Whatever the PCAC committee recommends on July 23 for BPC-157’s ulcerative-colitis nomination — and whatever rulemaking follows — will move the legal posture for that compound and leave GHK-Cu’s exactly where it has been since the cosmetic regulatory framework first encountered it.

So the which one question collapses into three smaller questions that the tissue-repair stack framing flattens into one: which anatomy, which form, and which regulatory floor. The honest read is that no answer is the same on both sides.

Different pathways, overlapping marketing — one peptide under review, the other not

Two peptides sold for the same job, doing different jobs in different anatomies, on evidence stacks that do not line up. One has a Phase 2 trial recruiting and a federal review scheduled for July. The other has a single small randomised trial in skincare with null objective endpoints and a federal review scheduled for February of the year after — for the injectable route specifically, the one the off-label market actually uses. That is what different pathways, overlapping results looks like once the marketing copy gets out of the way.

When the legitimate version exists

Wolverine Health is building the version that doesn’t ask you to take any of this on faith — physician-supervised peptide protocols, US-licensed compounding pharmacies, every batch third-party tested. For BPC-157 and GHK-Cu specifically, the prescribing question is unusually anatomy-and-route specific: which compound, in which form, for which indication, with what evidence behind it. The July 23 PCAC vote moves the answer for BPC-157 (orally, for ulcerative colitis); the February 2027 vote moves the answer for GHK-Cu (split by injectable and non-injectable, both nominations withdrawn, both slated for consultation). Two different votes, two different timelines, both on the same Section 503A list — all useful information for the supervising physician’s decision tree.

That is the landscape we are designing the protocol around. When the compounding service opens for these two molecules — what indications a supervising physician will actually prescribe for, what forms the US-licensed pharmacy will compound, and how the GHK-Cu cosmetic-versus-injectable distinction will be handled in the clinic — we will say so plainly. Join the waitlist if you want a heads-up the moment that version is available.